Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Testosterone Replacement on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Hypogonadotrophic Hypogonadism

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alper Sonmez, Gulhane School of Medicine
ClinicalTrials.gov Identifier:
NCT01533129
First received: December 13, 2011
Last updated: February 14, 2012
Last verified: February 2012
  Purpose

The study searched for answers to two questions

  1. What is the effect of testosterone replacement therapy on endothelial dysfunction, inflammation and insulin resistance?
  2. Regarding the above parameters, is there any difference between daily transdermal testosterone implementation and intramuscular injection performed in three weeks.

Condition Intervention Phase
Hypogonadotrophic Hypogonadism
Drug: Testogel 50 mg transdermal gel
Drug: Testosterone 250mg injection
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 4 Study That Evaluates the Effects of Two Different Testosterone Replacement Regiments on Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism.

Resource links provided by NLM:


Further study details as provided by Gulhane School of Medicine:

Primary Outcome Measures:
  • The alterations in the measures for endothelial functions [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The alterations in Endothelial functions are determined by measuring plazma ADMA levels, as a surrogate. ADMA measurement is pereformed by ELISA kit (Immundiagnotik, Bensheim, Germany)(Catalog Number 7828) with a minimal detection limit of 0.05µmol/L.

  • The alterations in the measures of insulin resistance [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The alterations in insulin sensitivity are estimated by using the HOMA index by the formula, HOMA-IR = (insulin x glucose)/405.

  • The alterations in the measures of inflammation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The alterations in the measures of inflammation are determined by measuring Human Pentraxin-3 levels. ELISA kiti /R&D Systems, Inc. Minneapolis, MN, ABD) (Catalog number DPTX30) with a minimal detection limit of 0.025ng/ml, intraassay CV of 3.8-4.4%, and interassay CV of 4.1-6.1% was used.


Enrollment: 106
Study Start Date: August 2008
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Daily testosterone transdermal gel Drug: Testogel 50 mg transdermal gel
50mg testosterone gel implementation on every night
Other Name: Testogel 50mg transdermal gel
Active Comparator: Injectable Testosterone esters
Testosteron 250mg injection per 3-4 weeks for 6 months
Drug: Testosterone 250mg injection
The testosterone 250mg ester IM injections performed in three weeks.
Other Name: Sustanon 250 mg amp.

  Eligibility

Ages Eligible for Study:   18 Years to 26 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men
  • Treatment naive
  • Hypogonadotrophic hypogonadism

Exclusion Criteria:

  • Previous history of androgen replacement
  • Chronic metabolic disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01533129

Locations
Turkey
Gulhane School of Medicine Department of Endocrinology and Metabolism
Ankara, Non US, Turkey, 06018
Sponsors and Collaborators
Gulhane School of Medicine
  More Information

No publications provided

Responsible Party: Alper Sonmez, Associate Professor in Medicine, Gulhane School of Medicine
ClinicalTrials.gov Identifier: NCT01533129     History of Changes
Other Study ID Numbers: GSM-022011
Study First Received: December 13, 2011
Last Updated: February 14, 2012
Health Authority: Turkey: Central Ethical Committee

Keywords provided by Gulhane School of Medicine:
Hypogonadism
Endothelial dysfunction
Inflammation
Insulin resistance
Testosterone replacement therapy

Additional relevant MeSH terms:
Hypogonadism
Inflammation
Insulin Resistance
Endocrine System Diseases
Glucose Metabolism Disorders
Gonadal Disorders
Hyperinsulinism
Metabolic Diseases
Pathologic Processes
Insulin
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Anabolic Agents
Androgens
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014